Entities / Company
Mesoblast.
pharmaceutical company
- Reports this week
- 1
- Active events
- 3
- Connections
- 26
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
Mesoblast is seeking conditional approval for its lead product in Japan.Some support3 reports
-
State Street Corporation accumulated a 5.1% stake in Mesoblast, with shares trading on the Australian Securities Exchange.Some support1 report
-
ASX 200 performance reflects market conditions, involving DroneShield and Mesoblast.Some support1 report2 developments inside
-
Institutional lending volume increased short selling pressure on Mesoblast.Some support1 report
-
Mesoblast, founded by Dr. Silviu Itescu in 2004, is currently seeking product approval and market access in Europe while trading on the Nasdaq stock exchange.Some support2 reports
-
Mesoblast received FDA approval for Ryoncil®, was added to S&P Dow Jones Indices, and appointed a new CEO.Well supported10 reports
-
Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.Speculative1 report1 development inside
Gone quiet
No new reports in 90+ days-
Mesoblast received FDA approval for a specific product on June 1st, led by CEO Silviu Itescu.Some support1 report
-
Mesoblast is part of the Australian Biotechs industry.Some support1 report
-
Mesoblast CEO Silviu Itescu announced support for the company's capital structure optimization.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Mesoblast this week
News at the entities that move Mesoblast most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Mesoblast
-
United States Food and Drug Administration StructuralFDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Moves Mesoblast
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Mesoblast
-
Australian Securities Exchange StructuralThe Australian Securities & Investments Commission implements enhanced disclosure obligations on market activities.Moves Mesoblast
-
Japan Shared contextSri Lanka joined the Sterling Assets Agreement and participated in the San Francisco Conference.Moves Mesoblast
-
State Street Corporation TransactionalTrump's pledge to unleash oil and gas benefits stocks, specifically involving Hilltop Airport.Moves Mesoblast
Connections
The 9 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Silviu Itescu Structural
Silviu Itescu founded Mesoblast and currently serves as its Chief Executive Officer.
-
FDA Structural
Mesoblast's commercial function and product availability are dependent on regulatory approvals and oversight provided by the FDA.
-
Nasdaq Structural
Mesoblast is a publicly traded company listed on the Nasdaq stock exchange.
-
United States Food and Drug Administration Structural
The US FDA formally granted RMAT designation to Mesoblast, establishing a regulatory oversight relationship.
-
Australian Securities Exchange Structural
Mesoblast's shares are publicly traded on the Australian Securities Exchange.
-
State Street Corporation Transactional
State Street Corporation accumulated a 5.1% equity stake in Mesoblast as part of a specific investment transaction.
-
Europe Shared context
Mesoblast is seeking market access and regulatory approval within the European continent.
-
Japan Shared context
Mesoblast is seeking conditional regulatory approval for its lead product within Japan.
Show all 9 connections
-
Sydney Shared context
Mesoblast operates within the market context of Sydney, Australia.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 events- State Street Corporation accumulated a 5.1% stake in Mesoblast, with shares trading on the Australian Securities Exchange.
- Institutional lending volume increased short selling pressure on Mesoblast.
- Mesoblast, founded by Dr. Silviu Itescu in 2004, is currently seeking product approval and market access in Europe while trading on the Nasdaq stock exchange.
July 2026
2 eventsShow 1 earlier month
June 2026
7 events- Trump pledged to unleash American oil and gas production.
- ASX 200 performance reflects market conditions, involving DroneShield and Mesoblast.
- Mesoblast received FDA approval for Ryoncil®, was added to S&P Dow Jones Indices, and appointed a new CEO.
- Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.
- Mesoblast received FDA approval for a specific product on June 1st, led by CEO Silviu Itescu.
- Mesoblast is part of the Australian Biotechs industry.
- Mesoblast CEO Silviu Itescu announced support for the company's capital structure optimization.